PLUS THERAPEUTICS, INC. CYTX Cash Flow

Plus therapeutics, inc. (CYTX)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Cash flows used in operating activities:
Net loss
-8,824	-10,887	-14,007	-16,863	-11,375	-12,634	-14,685	-17,161	-19,551	-22,686	-23,318	-23,896	-24,251	-22,046	-19,890	-12,978	-2,125	-18,744	-21,737	-32,649	-48,926	-37,368	-41,652	-37,528	-28,910	-26,177	-19,961	-25,948	-30,621	-32,279	-35,362	-32,450	-29,704	-32,451	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
547	896	1,317	1,646	1,950	2,004	1,998	2,074	2,206	2,151	2,006	1,660	1,333	1,182	1,126	1,157	1,171	1,093	1,015	945	832	779	986	1,314	1,590	1,630	1,390	1,140	913	933	946	908	881	855	0	0	0
Amortization of deferred financing costs and debt discount
504	550	549	623	641	578	510	501	593	707	820	904	941	954	979	947	954	979	973	1,158	1,196	1,220	1,249	1,125	982	893	829	790	885	930	946	710	708	711	0	0	0
Noncash lease expenses
16	12	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Provision for expired inventory
-	-	-	-	-	-	-	-	-	-	-	-	512	172	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of warrants
-4,864	-3,407	-488	-2,725	-2,443	-2,233	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Joint venture acquisition obligation accretion
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-782	-579	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Change in fair value of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	15,444	0	0	0	0	-	-	-	-	-	-	-	-	740	0	0	0
Change in fair value of warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	-	-	-	-
Change in fair value of option liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	-	-	-	-
Share-based compensation expense
90	127	136	193	261	355	490	582	697	753	743	845	962	1,080	1,349	1,540	1,899	2,041	2,152	2,799	2,873	3,101	3,451	3,218	3,422	3,608	3,720	3,765	3,835	3,904	3,645	3,572	3,377	3,316	0	0	0
Equity loss from investment in joint venture
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-48	-85	-127	-163	-165	-184	-193	-213	-209	0	0	0
Loss on asset disposal
-	-	-	-	-	-36	28	41	22	42	120	110	127	127	-5	-10	-10	-8	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Joint venture acquisition obligation accretion
-	-	-	-	-	-	-	-	-	-	-	-	-	24	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Provision for doubtful accounts
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,084	1,329	1,789	1,519	1,141	983	313	255	144	308	267	438	483	0	0	0
Provision for excess inventory
-	-	-	-	-	463	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Increases (decreases) in cash caused by changes in operating assets and liabilities:
Accounts receivable
800	1,203	4,708	-73	-362	173	178	-446	-47	-1,129	-721	-164	-1	179	-288	150	63	-328	317	-1,215	-2,554	-2,057	-935	685	2,028	1,209	2,147	1,206	1,801	1,810	-196	-211	89	670	0	0	0
Inventories
-243	-259	-134	-339	-350	-475	-409	-463	-385	-251	-738	-1,010	-684	-471	-690	620	-184	-490	-333	-441	164	815	642	169	533	459	739	883	278	-143	-742	-783	-178	-60	0	0	0
Other current assets
-178	211	177	43	200	-85	-205	-487	227	593	-144	240	-976	-633	174	394	575	637	-271	-463	-212	-510	112	56	168	24	2	73	54	324	0	0	0	-	-	-	-
Other assets
-276	-263	-314	-281	-48	-23	161	138	142	94	722	755	529	764	367	10	-84	-363	-897	-699	300	-11	861	548	-499	854	207	678	1,026	74	0	0	0	-	-	-	-
Other current assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Other assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Accounts payable and accrued expenses
787	-28	-353	-461	-1,381	-1,532	-1,345	-2,788	-1,889	-1,817	-1,406	-436	-1,333	-673	-838	-475	1,083	1,045	389	-182	-1,360	-1,147	5	-6	465	-409	-151	1,172	743	1,183	-786	-1,796	-665	-1,436	0	0	0
Deferred revenues
54	29	9	-21	-36	73	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other long-term liabilities
-86	-47	95	85	58	17	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenues, related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-638	-1,107	-1,107	-3,520	-2,882	-5,636	-5,636	-3,223	-1,992	0	0	0
Deferred revenues
-	-	-	-	-	-	-	-	-	-	6	4	8	-8	-46	-147	-22	3	-106	51	86	-100	69	-23	-185	-1,223	-3,757	-3,861	-3,744	-2,609	0	0	0	-	-	-	-
Long-term deferred rent
-	-	-	-	-	-	-	-	-	-	78	25	-172	-252	-306	-308	-318	-289	-281	-194	-157	-152	-125	-171	-124	-46	70	184	290	252	0	0	0	-	-	-	-
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-19,302	-19,533	-19,894	-21,415	-20,496	-20,468	-20,902	-21,981	-26,398	-30,330	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenues
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Long-term deferred rent
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Net cash used in operating activities
-4,138	-5,906	-9,430	-9,959	-11,126	-11,975	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-31,776	-31,749	-32,473	-35,323	0	0	0
Cash flows used in investing activities:
Purchases of property and equipment
72	67	13	61	86	133	0	0	0	-	228	57	3	67	177	219	493	611	516	794	664	764	775	554	725	519	663	750	1,260	1,204	1,179	1,013	454	560	0	0	0
Expenditures for intellectual property
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	255	255	255	155	0	0	0	0	-	-	-	-	-	-	-	-
License agreement termination fee
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	400	600	800	800	800	600	400	200	0	0	0	0	-	-	-	-
Net cash used in investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-1,030	64	-166	-208	-495	-613	-453	-731	-888	-1,343	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in investing activities
5,565	5,570	2,776	2,728	-86	-133	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,460	-1,204	-1,179	-1,013	-454	-560	0	0	0
Cash flows (used in) provided by financing activities:
Principal payments of long-term obligations
-	-	-	-	-	-	-	-	-	4,720	4,720	3,540	1,770	0	0	0	0	-	-	-	-	-	-	-	-	22,304	24,774	24,844	5,106	2,692	279	2,439	4,600	4,529	0	0	0
Payment of financing lease liability
121	131	75	28	28	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Joint venture purchase payments
-	-	-	-	-	-	-	-	-	-	-	-	-	1,774	1,774	2,274	2,000	1,623	1,649	1,196	247	2,262	2,316	2,340	2,359	221	0	0	0	-	-	-	-	-	-	-	-
Proceeds from exercise of employee stock options and warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4,151	4,144	143	258	225	572	577	466	1,413	0	0	0	-	-	-	-
Proceeds from exercise of employee stock options and warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Proceeds from sale of common stock, net
14,045	15,964	9,718	2,184	2,069	0	0	0	0	-	-	14,513	22,340	21,467	20,007	22,303	25,642	29,054	27,100	25,266	13,975	19,001	33,649	33,664	23,999	18,000	23,008	23,008	23,558	24,953	9,194	18,232	17,682	13,286	0	0	0
Costs from sale of common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	184	1,602	1,602	1,610	1,482	123	258	250	194	0	0	0
Dividends paid on preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	75	75	75	72	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in financing activities
-	-	-	-	-	-	-	-	-	-	-	-	17,212	17,609	15,874	17,670	17,080	20,797	32,548	33,897	27,758	30,874	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash (used in) provided by financing activities
10,722	12,631	16,660	8,682	9,209	7,168	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	9,780	25,304	24,679	20,137	0	0	0
Effect of exchange rate changes on cash and cash equivalents
0	-4	22	0	-27	16	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net decrease in cash and cash equivalents
12,149	12,291	10,028	1,451	-2,030	-4,924	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Effect of exchange rate changes on cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	17	82	140	153	70	0	-72	-103	-73	-85	-15	-21	-33	-106	-104	-81	-70	0	0	0	0	-	-	-	-
Net decrease in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-3,103	-1,778	-4,046	-3,800	-3,841	-284	11,121	11,082	399	-884	-2,356	-861	-3,604	-10,211	-7,423	-12,150	-17,995	-11,205	-23,175	-7,458	-8,248	-15,746	0	0	0
Supplemental disclosure of cash flows information:
Cash paid during period for:
Interest
1,068	1,188	1,412	1,508	1,367	1,331	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest
-	-	-	-	-	-	-	-	-	-	-	-	1,602	1,618	1,600	1,597	1,782	1,994	2,223	2,472	2,541	2,588	2,632	2,419	2,391	2,252	2,183	2,391	2,392	2,497	2,479	2,299	2,157	2,031	0	0	0
Supplemental schedule of non-cash investing and financing activities:
Conversion of preferred stock into common
-	-	-	-	-	-	-	27	27	23	0	0	0	-	-	-	-	10	26	26	26	16	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Declared dividend related to preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	75	75	75	72	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Capital equipment lease
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-22	79	0	0	0
Net increase in purchases of property and equipment included in accounts payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Net increase in purchases of property and equipment included in accounts payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0